Journal Options Hepatitis
Course Directors: David L. Thomas, MD, MPH, Robert G. Gish, MD
Featured Expert Commentary
Hal B. Jenson, MD, MBA
Chief Academic Officer, Baystate Medical Center
Dean, Tufts University School of Medicine Western Campus
Springfield, Massachusetts
Recent Articles
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. Ann Intern Med. 2006;144:705-714. Abstract
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
Bain VG, Kaita KD, Yoshida EM, et al. J Hepatol. 2006;44:671-678. Abstract
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y, Fleury H, Trimoulet P, et al. Hepatology. 2006;43:548-555. Abstract
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Berg T, von Wagner M, Nasser S, et al. Gastroenterology. 2006;130:1086-1097. Abstract
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Jensen DM, Morgan TR, Marcellin P, et al. Hepatology. 2006;43:954-960. Abstract
Variant of hepatitis B virus with primary resistance to adefovir.
Schildgen O, Sirma H, Funk A, et al. N Engl J Med. 2006;354:1807-1812. Abstract
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT, Gish RG, de Man R, et al. N Engl J Med. 2006;354:1001-1010. Capsule Summary | Abstract | Slides
Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.
El-Serag HB, Siegel AB, Davila JA, et al. J Hepatol. 2006;44:158-166. Capsule Summary | Abstract | Slides
Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Am J Gastroenterol. 2006;101:297-303. Capsule Summary | Abstract | Slides
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Gastroenterology. 2006;130:678-686. Capsule Summary | Abstract | Slides
|
Jointly sponsored by University of Alabama School of Medicine and Clinical Care Options, LLC.
Contact Info
Nov/Dec 2005
Collection
Hepatitis JournalOptions – November/December 2005
CME Program Director: Robert G. Gish, MD, David L. Thomas, MD, MPH
  
- Nezam H. Afdhal, MD, FRCPI
- Rena K. Fox, MD
- Neil Kaplowitz, MD
|
  
- Paul J. Pockros, MD
- Stuart Ray, MD
- Kathleen B. Schwarz, MD
|
Sept/Oct 2005
Collection
Hepatitis JournalOptions – September/October 2005
CME Program Director: Robert G. Gish, MD, David L. Thomas, MD, MPH
  
- Hal B. Jenson, MD, MBA
- Emmet B. Keeffe, MD, MACP
- Daryl T-Y Lau, MD, MSc, MPH, FRCP(C)
|
 
- Paul Martin, MD
- Philip Rosenthal, MD
- Richard K. Sterling, MD
|
|